⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APRE News
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
globenewswire.com
APRE
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com
APRE
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
globenewswire.com
APRE
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
globenewswire.com
APRE
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
globenewswire.com
APRE
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com
APRE